US FDA delays Lilly Alzheimer’s drug decision, calls for advisory panel
The U.S. Food and Drug Administration has delayed its decision on Eli Lilly’s LLY.N experimental treatment for early Alzheimer’s disease and will hold a meeting of ...
US FDA to soon decide on second round of Omicron-tailored boosters – WSJ
The U.S. Food and Drug Administration is close to making a decision on authorization of a second dose of updated COVID-19 vaccine boosters for high-risk people, the Wall Street ...
Eisai, Biogen get US FDA approval for Alzheimer’s drug, apply for full approval
The U.S. Food and Drug Administration on Friday approved the Alzheimer’s drug lecanemab developed by Eisai Co Ltd 4523.T and Biogen Inc BIIB.O for patients in the ...
FDA authorizes Covid-19 vaccine boosters for the immunocompromised
The U.S. Food and Drug Administration authorized a third dose of COVID-19 vaccines from Pfizer Inc and Moderna Inc for people with compromised immune systems.
The amended https://www....